Saturday 17 October 2026
Export OPK’s income statement to Excel — free account
OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.53
0.08
−4.97%
Follow OPK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.88 | 1.56 | 1.49 | 1.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(34.77) | (36.51) | (44.80) | (26.04) | |
P/B ratio |
0.92 | 0.75 | 0.72 | 0.96 | |
Price to Tangible BV |
4.21 | 3.54 | 3.83 | 5.03 | |
EV/Sales |
1.90 | 1.51 | 1.49 | 2.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 28.07 | |
EV/Operating CF |
(6.19) | (5.15) | (5.31) | (9.56) | |
EV/FCF |
(5.50) | (4.58) | (4.71) | (8.21) | |
Quick Ratio |
3.01 | 3.13 | 2.84 | 2.56 | |
Current Ratio |
3.70 | 3.97 | 3.61 | 3.35 | |
Net Debt/EBITDA |
(1.22) | 1.73 | (0.06) | 2.99 | |
Debt/Assets |
16.48% | 17.69% | 18.51% | 18.98% | |
Debt/Equity |
0.25 | 0.27 | 0.29 | 0.29 | |
Asset Turnover |
0.30 | 0.29 | 0.29 | 0.31 | |
Operating CF/Net income |
(1.60) | 0.83 | 0.35 | 5.17 | |
Capex/Depreciation |
(0.14) | (0.11) | (0.08) | (0.13) | |
Interest Coverage |
4.23 | (3.39) | (4.66) | (0.61) | |
Research and Development Expense of Revenue |
19.83% | 22.08% | 23.51% | 20.28% | |
Selling, General and Administrative Expense of Revenue |
35.47% | 34.03% | 39.14% | 32.35% | |
Intangible Assets out of Total Assets |
0.51 | 0.52 | 0.53 | 0.52 | |
Share Based Compensation of Revenue |
1.96% | 1.96% | 2.20% | 1.37% | |
Graham Net Nets |
(0.05) | (0.09) | (0.13) | (0.13) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(15.48%) | (23.81%) | (23.68%) | (6.00%) | |
Free Cash Flow Yield |
(18.41%) | (21.19%) | (21.26%) | (12.69%) | |
Revenue per Share |
0.20 | 0.20 | 0.16 | 0.22 | |
Operating CF per Share |
(0.04) | (0.03) | (0.03) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | (0.03) | (0.06) | |
Cash per Share |
0.53 | 0.49 | 0.45 | 0.40 | |
Shareholders Equity per Share |
1.68 | 1.69 | 1.59 | 1.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.68 | 1.69 | 1.59 | 1.57 | |
Free Cash Flow |
(37.77) | (28.49) | (21.11) | (46.36) | |
Working Capital |
457.81 | 435.20 | 386.98 | 350.87 | |
Capital Expenditures |
(3.12) | (2.57) | (1.80) | (2.86) | |
Net Current Asset Value |
(62.89) | (82.10) | (116.82) | (145.05) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
100.58 | 104.14 | 87.89 | 90.63 | |
Average Payables |
56.77 | 44.09 | 51.77 | 53.36 | |
Average Inventory |
62.18 | 61.31 | 64.20 | 64.10 | |
Average Assets |
2,125.81 | 2,066.08 | 1,992.56 | 1,901.22 | |
Average Common Equity |
1,354.45 | 1,316.70 | 1,258.14 | 1,240.54 |
Columns are period end dates